Armed with a Master of Science in Physical Therapy degree, Bill Murphy is bringing more than 17 years of experience in orthopedics and spine sales to CoreLink as one of four new regional Vice Presidents of Sales. CoreLink, a spine company based in St. Louis, Missouri, indicates that it is bringing new talent on board due to an aggressive investments in new product development and a commitment to its surgeon and distributor partners.
Bill Murphy: New Regional Vice President of Sales at CoreLink

Murphy commented, “One of my first priorities will be to engage surgeons, distributors, hospitals, and ambulatory surgery centers in the market and work to create opportunities and alignment amongst all stakeholders.”
“Bill impressed me with his technical and clinical knowledge of spinal products and procedures. More impressively, he seems to have a natural understanding of CoreLink’s unique position as both a technology innovator and vertically integrated manufacturer that can aid greatly in aligning the interests of surgeons, distributors, hospitals, and ambulatory surgery centers in the market,” said Derek Kuyper, vice president of CoreLink.
Murphy told OTW, “I look forward to growing in the Northeast, while engaging with distributor and surgeon partners. In addition, I am excited to share the best-in-class implants and instruments we offer.”
“While the COVID pandemic has lowered elective case volume across the industry, CoreLink has invested in new product development, strengthened internal processes, and continued to rapidly grow customers. We believe expanding our sales management team during this time is a great opportunity to increase market share in a rapidly evolving market,” said Derek Kuyper.
The company anticipates several product launches over the next few months.

Discussion
This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?
Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.
We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.
Join the conversation
Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.